Mr. Mahady has extensive strategic and operational experience in all aspects the biopharmaceutical industry. He has a successful record of creating value by transforming businesses, developing operational excellence and being able to lead the integrated efforts need to develop and introduce market changing products as evidenced by his more than 30 product launches.
Mr. Mahady held significant leadership positions during his 30-year career with Wyeth Corporation culminating with his role as President of Wyeth Pharmaceuticals and Senior Vice President of Wyeth Corporation, with responsibility for directing Wyeth’s $20 billion global pharmaceutical business. During his tenure at Wyeth, Joe helped lead the transformation of Wyeth from a mid-sized, traditional pharmaceutical company to one of the largest and most diverse biopharma companies in the industry. He retired from Wyeth in 2009. Since his retirement Mr. Mahady has provided consulting services on both strategic and operational biopharmaceutical matters and served as a director on the boards of Albemarle, EKR Therapeutics and Strongbridge Biopharma, Windtree Therapeutics (Current) and as Chairman of Lumara Health (formerly KV Pharmaceuticals).
Mr. Mahady received his B.S. degree in Pharmacy from St. John’s University College of Pharmacy and his MBA in Pharmaceutical Studies from Fairleigh Dickinson University.
George Zorich has been in pharmaceutical fields for over 30 years, including Big Pharma, Biotech, Generics, Distribution companies and Start-ups—the last 15 years focused on building up and selling companies while CEO or president, oftentimes working with private equity to develop the best exit strategy for each company.
Most recently, Mr. Zorich was CEO of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich’s ataxia using DNA based therapies. Prior to that Mr. Zorich was president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products, leading to the sale to Mylan Pharmaceuticals for $550MM in late 2010. Before that, Mr. Zorich was president of Sabex-USA leading to its sale to Sandoz for $480MM in 2004, where he then headed up the Sandoz US injectable business. Before that, he was president of GIV, which at that time was the largest distributor of vaccines to physician offices, leading to the sale to Henry Schein, the multibillion-dollar distributor. Mr. Zorich has also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and Eli Lilly and Company.
Mr. Zorich’s goal has been to strive for policy changes that provide affordable medications to American consumers and to also provide a consistent and reliable supply of injectable pharmaceuticals to the U.S. hospital marketplace. He is also an advocate for more entrepreneurship, leadership and selling skills being taught to our college students today.
Mr. Zorich is currently a board member of the American Society of HealthSystem Pharmacists (ASHP) Foundation; Custopharm, a developer of injectable products; and serves on the University of Wisconsin School of Pharmacy Board of Visitors. He is a past board member of the Generic Pharmaceutical Association (GPHA) and the American College of Phlebology (ACP). He is also a board member of Love, INC a charity and Brothers United, a mentoring program for at risk high schoolers in North Chicago.
Mr. Zorich received his pharmacy degree from the University of Wisconsin.
Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals including Big Pharma, biotech, and academic startups as well as interactions advising venture capital and private equity.
Dr Spiegel spent over 25 years at Schering-Plough where he joined as the first Director for Oncology Clinical Research, and subsequently held a series of senior executive positions, including Senior Vice President for worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he took numerous drug candidates through clinical development and was involved with over 30 NDA approvals at the FDA. For the last five years Dr. Spiegel has been a consultant to the biotech industry and has served on the Boards of multiple biotech companies. He currently serves on the Board of Directors of Geron Corp, Sucampo, and Edge Therapeutics. He is currently the principal of Spiegel Consulting LLC and an Assistant Professor of Medicine at Weill Cornell Medical College. He is also a Senior Advisor to private equity firm Warburg Pincus and an Advisor to the Israel Biotech Fund.
Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. He completed his specialty training at the National Cancer Institute, National Institutes of Health (NIH).